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ABSTRACT
Objectives What is the most effective pharmacological 
intervention for glycaemic control in known type 2 
diabetes mellitus (DM) without prior insulin treatment and 
newly started on systemic glucocorticoid therapy?
Design We conducted a systematic literature review.
Data sources We searched MEDLINE, Embase and 
Cochrane Library databases and Google for articles from 
2002 to July 2018.
Eligibility criteria We combined search terms relating to 
DM (patients, >16 years of age), systemic glucocorticoids, 
glycaemic control, randomised controlled trials (RCTs) and 
observational studies.
Data extraction and synthesis We screened and 
evaluated articles, extracted data and assessed risk 
of bias and quality of evidence according to Grading 
of Recommendations Assessment, Development and 
Evaluation guidelines.
Results Eight of 2365 articles met full eligibility criteria. 
Basal-bolus insulin (BBI) strategy for patients under 
systemic glucocorticoid therapy was comparatively 
effective but provided insufficient glucose control, 
depending on time of day. BBI strategy with long-acting 
insulin and neutral protamin Hagedorn as basal insulin 
provided similar overall glycaemic control. Addition of 
various insulin strategies to standard BBI delivered mixed 
results. Intermediate-acting insulin (IMI) as additional 
insulin conferred no clear benefits, and glycaemic control 
with sliding scale insulin was inferior to BBI or IMI. No 
studies addressed whether anticipatory or compensatory 
insulin adjustments are better for glycaemic control.
Conclusion The lack of suitably designed RCTs and 
observational studies, heterogeneity of interventions, target 
glucose levels and glucose monitoring, poor control of DM 
subgroups and low to moderate quality of evidence render 
identification of optimal pharmacological interventions 
for glycaemic control and insulin management difficult. 
Even findings on the widely recommended BBI regimen 
as intensive insulin therapy for patients with DM on 
glucocorticoids are inconclusive. High-quality evidence 
from studies with well-defined DM phenotypes, settings 
and treatment approaches is needed to determine optimal 
pharmacological intervention for glycaemic control.
PROSPERO registration number CRD42015024739.
InTRODuCTIOn
The worldwide prevalence of type 2 diabetes 
mellitus (DM) in adults has doubled since 
1980 to 8.5% in 2014.1 While compar-
atively stable in recent years, the preva-
lence of hospitalised patients with DM is 
25%–40%.2 3 Steroid treatment in patients 
with DM is common.4 5 However, steroids 
are the main cause of drug-induced hyper-
glycaemia6 due to their effect of increasing 
basal endogenous glucose production and 
lowering insulin sensitivity.7–9 Over half of 
patients receiving high-dose steroids develop 
hyperglycaemia.10 Significantly, steroids exac-
erbate hyperglycaemia in patients with pre-ex-
isting DM11 12 and enhance the likelihood of 
complications, length of stay and mortality in 
these patients.3 13–18 
The importance of detecting and actively 
managing hyperglycaemia in patients with 
DM undergoing glucocorticoid therapy 
is acknowledged.13 19 20 However, current 
management strategies are suboptimal,13 21 
and the limited evidence available does not 
Strengths and limitations of this study
 ► Systematic review with extensive literature search 
to provide comprehensive data on a very common 
but unresolved daily problem in managing type 2 di-
abetes mellitus (DM).
 ► Lack of comparability between studied populations 
and interventions and low to moderate quality of ev-
idence does not permit full quantitative analysis and 
provision of formal recommendations on specific 
insulin regimens.
 ► Firm conclusions on optimal pharmacological in-
terventions for glycaemic control awaits studies of 
sufficient power, quality and testing of well-defined 
DM phenotypes, settings and treatments.
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adequately inform the physician.6 This is all the more 
important as the type and doses of administered gluco-
corticoids and the potencies (and duration of action) of 
different systemic glucocorticoids vary widely.22–24 Shorter 
courses of steroids may lead to brief periods of hypergly-
caemia that do not require further intervention, though 
hyperglycaemia and other side effects can occur at a wide 
range of doses.25 However, longer courses of steroids at 
higher doses can lead to symptomatic hyperglycaemia.26 27 
Optimal treatment strategies for glycaemic control are, 
therefore, vital.
The aim of this study was to conduct a systematic review 
of treatment strategies for glycaemic control in persons 
with type 2 DM on diet or oral hypoglycaemic agents 
(OHA) and newly initiated glucocorticoid therapy. 
Specifically, we sought to identify the most effective phar-
macological intervention for glycaemic control. We eval-
uated also whether the simultaneous start of insulin with 
glucocorticoids (anticipatory treatment adjustment) or 
delayed start of insulin, when blood glucose level (BGL) 
exceeds normal upper limits (compensatory treatment 
adjustment), is more effective.
METhODS
Protocol and registration
The review methods and eligibility criteria were speci-
fied in advance, documented in a study protocol, regis-
tered online with the International Prospective Register 
of Systematic Reviews, 31 May  2016, and recorded with 
a Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement.28 We updated the protocol once 
on 21 October 2016 to broaden inclusion criteria.
Eligibility criteria
For eligibility, we followed the Patients, Interventions, 
Comparisons, Outcomes and Settings (PICOS) criteria.28 
Patients: We included articles on non-critically ill (non-in-
tensive care unit) in-patients or outpatients (>16 years of 
age) who suffered from type 2 DM treated with diet or 
OHA (ie, biguanide, gliflozins, gliptins, sulfonylureas, 
glinides, incretins or glitazones) and were started on a 
once or multiple daily oral or intravenous glucocorticoid 
therapy (ie, hydrocortisone, prednisone, prednisolone, 
methylprednisolone, dexamethasone, betamethasone 
or fludrocortisone) irrespective of the indication. Inter-
ventions: The articles and studies had to address specific 
treatment interventions for glycaemic control, including, 
for example, stopping routine DM medication and 
starting insulin treatment. Comparisons: We included all 
types of comparisons of the study population with those 
(1) without DM, (2) without glucocorticoid treatment, 
(3) with adjusted OHA, or (4) with differing insulin 
treatments. Outcomes: We accepted outcomes reflecting 
glycaemic control, that is, time outside target glucose 
range, mean BGL, hypoglycaemic or hyperglycaemic 
episodes, and daily insulin dose. Settings: We included 
randomised controlled trials (RCTs) and observational 
studies, that is, cohort studies, case–control studies or 
cross-sectional studies, without imposing any restriction 
on language, country of origin or publication type. We 
excluded letters to the editor and conference abstracts. 
We consulted also guidelines, reviews and expert opin-
ions. We considered only papers published after 2002 
because of the subsequent introduction of long-acting 
insulin; long-acting insulins are, nowadays, an integral 
part of treatment in insulin-dependent DM.
Search strategy
We identified articles based on search terms related to 
DM and glucocorticoids in the following databases: 
MEDLINE and PreMEDLINE using OVID, Embase and 
Cochrane Library electronic databases (online supple-
mentary table 1). The combined use of the databases 
(PubMed, MEDLINE, Embase and Cochrane) allows 
coverage of up to 97% of available publications.29 To 
enhance coverage further, we conducted also a Google 
search to retrieve grey literature with exclusive focus on 
pdf files. The search was conducted on 8 July 2016 and 
updated on 2 July 2018.
Study selection
MT and SKR independently screened a sample of 100 
papers by studying the titles and abstracts according to 
the selection criteria ‘adult persons with pre-existing DM 
who received a glucocorticoid therapy’. If no abstract was 
available but the title appeared relevant, MT and SKR 
reviewed the full text. One abstract was translated from 
Japanese.
MT and SKR then evaluated the first 100 papers in 
consensus to establish the basis for consistent screening 
of all further papers. MT performed the screening of 
all papers and SKR independently double screened a 
random sample of 10% of all articles. All articles were 
assigned to one of the three eligibility groups: ‘yes’, ‘no’ 
and ‘maybe’. The ‘maybe’ group was discussed by MT 
and SKR for eligibility after full-text review in a consensus 
conference. Initial review of eligible articles revealed 
the necessity for modification of the inclusion criterion 
‘≥20 mg/day prednisolone equivalent for ≥5 days’ to 
‘intermediate-dose or high-dose glucocorticoid therapy’ 
because a large number of articles did not specify exact 
dosages of glucocorticoids.
MT and SRK independently performed a full-text 
review of all eligible papers for inclusion, considering the 
PICOS criteria. Disagreements between reviewers were 
resolved by consensus. Finally, the reference lists of all 
included articles were screened for additional eligible 
papers, guidelines and review articles.
Data extraction and quality assessment
We extracted the following data from the included arti-
cles: study population, participants, and age. Then, we 
assessed indication, dosage and duration of glucocorti-
coid therapy, target glucose, insulin strategy, the manage-
ment of OHA interruption, continuation or adjustment 
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of dosages and outcome measures, such as time in target 
glucose range, mean BGL, hypoglycaemic and hyper-
glycaemic episodes and insulin requirement. Differing 
assessments were discussed and resolved between MT and 
SKR.
We used the Cochrane risk of bias tool30 to evaluate the 
risk of bias in RCTs and applied the key criteria of the 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) guidelines for observational 
studies to assess the methodological quality of nonran-
domised studies.31 The overall quality of evidence was 
assessed using the GRADE criteria.32
Data synthesis
We performed a descriptive analysis of RCTs and observa-
tional studies. This was because the lack of concordance 
in the study designs in the included articles precluded 
the performance of meta-analyses. Included articles 
were evaluated and compared in detail and the findings 
were summarised.
Patient or public involvement
Neither the patients nor the public were directly involved 
in the development of the research question, selection 
of the outcome measures, design and implementation of 
the study, or interpretation of the results.
RESulTS
Study inclusion
Our initial search generated 3521 articles. A total of 2365 
articles remained after eliminating duplicate entries. Of 
these, 37 qualified for full-text review. Eight articles met 
full eligibility criteria, namely, four RCTs33–36 with open-
label and parallel group designs, one RCT with open-
label and cross-over design37 and three observational 
studies38–40 with a retrospective cohort design (figure 1 
and table 1).
The eight articles reported studies that included a 
total of 481 persons, 343/481 persons with DM and 
138/481 persons with glucocorticoid-induced hypergly-
caemia. One study included persons with both type 1 and 
type 2 DM but did not take this distinction into consider-
ation for outcomes.33 At least 85/481 persons had prior 
treatment with insulin; three studies did not provide 
this information.33 34 39 Seven studies included inpatients 
only,33–36 38–40 and one study included both inpatients and 
outpatients.37 Capillary blood glucose was measured four 
times a day by continuous glucose monitoring or by using 
all available capillary and serum blood glucose readings 
(table 2). The upper limit was a BGL of 10 mmol/L in all 
studies. The lower BGL limit was 3.9–4.5 mmol/L in all 
but two studies in which it was 5.6 mmol/L33 40 (table 2). 
Insulin dose adjustments were applied if BGL was outside 
the target glucose range, according to specific study 
protocols.
In six studies, authors treated control groups with a 
basal-bolus insulin (BBI) regimen using insulin glargine 
as basal insulin,33–36 38 39 in one study with a BBI regimen 
using twice-daily insulin detemir,40 and one study using 
sliding-scale insulin (SSI) in addition to established DM 
medication.37 Strikingly, treatment interventions in the 
experimental groups diverged substantially. One study 
compared glycaemic control of BBI regimen in patients 
with type 2 DM without prednisolone with those with pred-
nisolone treatment.38 Another study compared glycaemic 
control of BBI regimen with SSI regimen.40 One study 
compared addition of SSI to routine DM medication 
with the addition of intermediate-acting insulin (IMI).37 
Three studies compared BBI regimens with long-acting 
insulins to BBI regimens with intermediate-acting neutral 
protamin Hagedorn (NPH) insulin,35 36 39 but in one of 
these studies, NPH was given in three equal prandial 
doses.36 One study compared BBI regimen with long-
acting insulin to the same regimen with the addition of 
NPH insulin.34 Finally, the most recent study added the 
insulin type that matched the glycaemic profile of the 
administered glucocorticoid.33 This divergence in study 
designs of RCTs precluded a clean and coherent quanti-
tative meta-analysis.
BBI strategy in persons under systemic glucocorticoid therapy
Two observational studies38 40 report BBI as superior 
in glucocorticoid-treated patients with type 2 DM.41 42 
Gosmanov et al40 found more hyperglycaemic events in 
patients with type 2 DM under dexamethasone for 3 days 
(for a hematological malignancy) when treated with SSI 
therapy compared with a BBI therapy (table 2). In the 
SSI group, the mean daily BGL was significantly higher 
(p<0.001), and the average insulin requirement was 
significantly lower (p<0.001). No hypoglycaemic events 
occurred in either groups, but 3/28 (11%) persons 
treated with SSI were referred to an intensive care unit 
because of hyperglycaemic events.
Burt et al38 studied the effectiveness of a BBI regimen 
in hospitalised patients with type 2 DM treated with pred-
nisolone in the morning for an acute medical condition 
compared with those without glucocorticoid treatment. 
Half of the calculated daily dose was given as long-acting 
insulin glargine at 21:00  and half as bolus evenly split into 
three meal dosages of rapid-acting insulin with additional 
correctional insulin when necessary. The mean daily 
BGL was significantly higher in the prednisolone group 
(p<0.001) (table 2). More specifically, BGL was signifi-
cantly higher at 17:00 and 21:00, but not significantly 
higher at 07:00 and 12:00 In addition, the daily insulin 
dose was significantly higher in the prednisolone-treated 
group than in the control group, especially at 12:00 and 
17:00. Thus, BBI treatment provided insufficient glucose 
control, most notably in the afternoon and evening.
Comparison of BBI regimen with long-acting insulin to nPh as 
basal insulin
Two RCTs35 36 and one observational study39 compared 
NPH insulin with the long-acting insulin glargine in a 
BBI regimen for their efficacy in controlling BGL in 
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hospitalised persons treated with medium-dose to high-
dose glucocorticoids.36 39 The studies differed substan-
tially in their design (table 1). Radhakutty et al35 included 
persons with or without type 2 DM who were treated with 
a single dose of glucocorticoids for respiratory disease or 
gout. Glargine was administered in the control group and 
NPH in the experimental group at 07:00. Ruiz de Adana 
et al36 studied patients with type 2 DM receiving multiple 
daily doses of glucocorticoids for respiratory disease. The 
glargine group received its basal insulin as one dose at 
09:00, and the NPH group received it before breakfast, 
lunch and dinner in three equal doses. Dhital et al39 retro-
spectively studied adults treated with prednisone who 
were on a BBI regimen with either insulin glargine or 
NPH. Notably, the target glucose range, the time of appli-
cation and the number of doses of basal insulins were not 
indicated here, and persons with hyperglycaemia without 
underlying type 2 DM were also included.
All three studies show a similar overall glycaemic 
control for NPH or glargine as basal insulin.35 36 39 More 
specifically, the mean daily BGL and the number of mild 
hypoglycaemic episodes per day were similar (table 2). 
Notably, severe hypoglycaemia (BGL <2.22 mmol/L) 
occurred in two persons in the NPH group in the study 
by Ruiz de Adana et al.36 Only Dhital et al39 found a signifi-
cantly lower daily insulin requirement in the NPH group.
Figure 1 Flow diagram of study selection. PICOS, patients , interventions, comparisons, outcomes and settings. 
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Addition of insulin to established DM medication
Gerards et al37 compared the addition of SSI insulin 
compared with IMI to established DM medication for 
glycaemic control. The types of insulin were not further 
defined. Half of the persons had prior insulin treatment. 
The addition of IMI resulted in significantly longer time 
in target glucose range (p<0.001) and lower mean daily 
BGL (p<0.05). This was achieved with an increased insulin 
requirement in the IMI group. Remarkably, the mean 
daily BGL of both groups (SSI 13.5±2.8, IMI 12.4±2.9) was 
higher than those of all other studies (table 2).
Two RCTs added insulin to an existing BBI regimen in 
persons with or without type 2 DM33 34 (table 1). Grom-
mesh et al34 studied the addition of NPH insulin together 
with a glucocorticoid to a BBI regimen. The algorithm for 
NPH dosing was based on glucocorticoid type, dose and 
pre-existing DM diagnosis. The study showed that there 
was no advantage in this for glycaemic control, mean total 
daily insulin dose, or hypoglycaemia and hyperglycaemia 
(table 2). Similarly, an RCT by Lakhani et al33 studied 
the addition of a so-called ‘correctional insulin’ together 
with the glucocorticoid to a BBI regimen. The type of 
correctional insulin matched the glycaemic profile of 
the type of administered glucocorticoid, for example, 
NPH insulin for prednisolone or insulin glargine for 
dexamethasone treatment.33 Correctional insulin signifi-
cantly improved ‘time in target premeal glucose range’ 
(defined as 5.6–10 mmol/L (p=0.002) and mean daily 
BGL (p=0.0001) but not time in ‘bedtime target glucose 
range’ (p=0.09). The hyperglycaemic events were reduced 
(p<0.001). No data were provided on subgroups without 
DM or with type 1 DM and on daily insulin doses.
Anticipatory or compensatory approach to glycaemic control
We aimed to determine whether anticipatory or compen-
satory adjustments are better for glycaemic control. No 
screened or included study addressed this issue. While 
screening articles, we found some recommendations 
about this in guidelines41 43–45 and reviews,46–50 and we 
address this issue in the discussion section.
Risk of bias and grading of evidence
Risk of bias was assessed in five RCTs for seven domains 
and four outcomes (mean BGL, time in target glucose, 
daily insulin dose and hypoglycaemia) (online supple-
mentary table 2a). All RCTs were unblinded for partici-
pants and personnel. Although placebo effects are very 
unlikely, unblinding may have affected the attention 
of staff. This might be the most relevant risk for bias in 
these studies. The lack of random sequence generation 
and allocation concealment might be another common 
bias. The three observational studies were classified as 
having low,38 middle39 and high40 ranges of risk of bias 
(online supplementary table 2b). The most common risk 
of bias was the failure to control confounding. Notably, 
an overall risk of bias of an outcome for all five RCTs is 
not so informative because the treatment interventions 
were not comparable.
Applying the GRADE criteria on each individual study, 
we had to decrease the level of evidence for the primary 
outcomes ‘mean BGL’ and ‘time in target glucose range.’ 
This was mainly because of risk of bias and publication 
bias and because of inconsistency and imprecision in the 
five RCTs and one observational study (for the overall 
rating of quality of evidence in RCTs and observational 
studies, see online supplementary table 3). Hence, we 
classified the overall quality of evidence for the individual 
interventions as moderate,33 36 37 low35 38 39 or very low.34 40
DISCuSSIOn
Glucocorticoid treatment inevitably leads to hypergly-
caemia in persons with type 2 DM. We systematically 
reviewed the available evidence on pharmacological inter-
ventions for effective glycaemic control. We found, first, 
that there is some uncertainty as to the optimal manage-
ment of glucocorticoid-induced hyperglycaemia in DM. 
The lack of studies reporting high-quality evidence makes 
it difficult to provide formal and final recommendations. 
This review shows that the available evidence is of low 
to moderate quality. Second, the reviewed studies speak 
in favour of the use of BBI without a specific preference 
for long-acting or IMI as basal insulin, but these studies 
do indicate that SSI should be abandoned. Third, two 
studies suggested that pharmacodynamic profiles of insu-
lins should be reconciled with corresponding profiles of 
glucocorticoids. However, there is insufficient evidence 
to recommend this. Finally, the reviewed studies do 
not clarify whether one should initiate anticipatory or 
compensatory insulin treatment.
BBI is widely accepted and recommended as inten-
sive insulin therapy in DM.42 51 52 However, the question 
remains whether BBI performs best in type 2 DM under 
glucocorticoid treatment. Five open-label RCTs and three 
observational studies included in this systematic review 
address this issue. Gosmanov et al40 shows that BBI is 
better than SSI in terms of glycaemic control. This is in 
line with data from various clinical settings that support 
improved hyperglycaemic control using BBI compared 
with SSI.53 54 Gerards et al37 corroborates that SSI delivers 
poorer control compared with IMI when used as an addi-
tion to the routine DM regimen. Although very popular 
among non-endocrinologists, these findings suggest that 
SSI treatment should not be prescribed in this setting 
anymore. On the other hand, Burt et al38 did find that 
glycaemic control was insufficient at 17:00  and 21:00 
when using BBI with long-acting insulin in patients with 
type 2 DM treated with prednisolone compared with 
those without prednisolone treatment. These findings are 
in line with previous reports of afternoon and evening 
hyperglycaemia under glucocorticoids in persons without 
DM.24 27 55 Thus, BBI with long-acting insulin does not 
offer a final solution.
The intermediate-acting NPH insulin provides good 
control of afternoon peaks of blood glucose caused by 
glucocorticoids. This approach might have an advantage 
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over long-acting insulin because its effects show a similar 
timeline to that of glucocorticoid-induced afternoon 
peaks of hyperglycaemia.56 57 Three of the reviewed arti-
cles35 36 39 compared NPH insulin with insulin glargine 
as basal insulin in a BBI treatment in randomised 
controlled35 36 and retrospective39 studies, finding no 
significant differences in glycaemic control. However, 
NPH insulin caused more hypoglycaemic events when 
NPH and bolus insulin were administered in equal 
preprandial doses for the purpose of controlling hyper-
glycaemia in persons receiving multiple daily doses of 
glucocorticoids.36 Such a protocol may not be flexible 
enough in that it does not give sufficient consideration 
to the night-time fasting period and the associated risk of 
nocturnal hypoglycaemia. Insulin requirement, however, 
was higher in BBI with long-acting insulin compared 
with NPH as basal insulin in two of the studies,36 39 but it 
was similar in the other.35 The addition of NPH together 
with the glucocorticoid in the BBI treatment also failed 
to improve glycaemic control.34 The most recent study 
by Lakhani et al33 suggests a unique approach to better 
match the pharmacodynamic properties of insulins and 
glucocorticoids. This resulted in significantly lower mean 
daily BGL and premeal time in target glucose range. 
While the approach of Lakhani et al33 appears to be prom-
ising, it does need to be corroborated in a larger study.
We found no primary data comparing anticipatory 
with compensatory treatment adjustments for glycaemic 
control when starting glucocorticoids. This lack of data is 
a source of some divergence in expert opinions in guide-
lines. The American Endocrine Society Clinical Practice 
Guidelines41 recommends an anticipatory approach with 
discontinuation of OHA at the time of hospital admission 
and initiation of insulin with persistent hyperglycaemia. 
In exceptional cases, selected persons who are stable, 
eating regularly and have no contraindication ‘may be 
candidates for continuation of previously prescribed 
OHA’. The Canadian Diabetes Association guideline45 
recommends that ‘glycemic monitoring for 48 hours after 
initiation of steroids may be considered’. In contrast, the 
Joint British Diabetes Societies for inpatient care guide-
line,19 and the Imperial College Clinical Guidance58 
recommend the up-titration of OHA first. They recom-
mend adding19 or switching58 to insulin if BGL remains 
above 10 mmol/L. Reports of experience or evidence 
to suggest the use of DDP-4 inhibitors, GLP-1 receptor 
agonists or SGLT-2 inhibitors are lacking.
The strength of our systematic review is that it makes 
an important contribution to DM management. It does 
this by highlighting the unresolved challenge of good 
glycaemic control in patients with DM who are on systemic 
glucocorticoid therapy and by reporting an extensive liter-
ature search on hyperglycaemic control in these patients. 
However, we cannot draw conclusions from our system-
atic analysis on the most effective management approach. 
This is largely due to the low to moderate quality of avail-
able evidence and the lack of comparability between the 
reviewed studies. In fact, this review draws attention to 
the heterogeneity of the experimental designs and the 
lack of well-powered, high-quality studies. Given that 
the populations, interventions, target glucose levels and 
glucose monitoring differed from study to study, the main 
limitation is that we can only provide a descriptive review 
of the studies but not formal recommendations. Well-de-
signed studies with more homogeneous patient popula-
tions are needed in order to answer the questions raised 
in this review. The present review focused on the popu-
lation of persons with pre-existing type 2 DM without 
prior insulin treatment. However, we included articles 
with mixed populations, namely, persons with type 2 DM 
with or without prior insulin treatment and type 1 DM, 
because there is an insufficient number of articles with 
the specific subgroup of interest. We acknowledge that 
this is not standard practice in systematic reviews.
COnCluSIOn
Glucocorticoid therapy exacerbates hyperglycaemia 
in patients with pre-existing DM. Current manage-
ment strategies give insufficient guidance for glycaemic 
control in persons started on glucocorticoids. The lack 
of relevant RCTs and observational studies, heteroge-
neity of populations, interventions, target glucose levels 
and glucose monitoring in available studies, and low to 
moderate quality of available evidence make it difficult 
to identify pharmacological interventions for effective 
glycaemic control. Even for the widely recommended use 
of a BBI regimen as intensive insulin therapy in DM, the 
data on this regimen in patients with DM on glucocorti-
coids are inconclusive. Indeed, the findings of our system-
atic review clearly speak in favour of the call to action on 
research in inpatient DM management of The PRIDE 
group59 and in outpatient care. A concerted effort of 
diabetes societies would be needed to develop powerful 
study designs that take into account different DM pheno-
types, settings and treatment approaches.
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